Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MalVIP1
NCT05652504Phase 1Suspended
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2026
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Sanaria PfSPZ Vaccine in malaria (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Composite of adverse maternal and birth outcomes at 1 year. Started Sep 2026; status: suspended.
02
Drugs
Sanaria PfSPZ Vaccine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05652504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05652504.